The impact of treatment modality on survival in patients with clinical node-positive bladder cancer: results from a multicenter collaboration

被引:17
作者
Afferi, Luca [1 ]
Zamboni, Stefania [1 ,2 ]
Karnes, R. Jeffrey [3 ]
Roghmann, Florian [4 ]
Sargos, Paul [5 ]
Montorsi, Francesco [6 ]
Briganti, Alberto [6 ]
Gallina, Andrea [6 ]
Mattei, Agostino [1 ]
Schulz, Gerald Bastian [7 ]
Hendricksen, Kees [8 ]
Voskuilen, Charlotte S. [8 ]
Rink, Michael [9 ]
Poyet, Cedric [10 ]
De Cobelli, Ottavio [11 ]
di Trapani, Ettore [11 ]
Simeone, Claudio [2 ]
Soligo, Matteo [3 ]
Simone, Giuseppe [12 ]
Tuderti, Gabriele [12 ]
Alvarez-Maestro, Mario [13 ,14 ]
Martinez-Pineiro, Luis [13 ,14 ]
Aziz, Atiqullah [15 ]
Shariat, Shahrokh F. [16 ,17 ,18 ,19 ,20 ]
Abufaraj, Mohammad [16 ,21 ,22 ]
Xylinas, Evanguelos [23 ]
Moschini, Marco [1 ,6 ]
机构
[1] Luzerner Kantonsspital, Dept Urol, Luzern, Switzerland
[2] Univ Brescia, Spedali Civili Hosp, Dept Urol, Brescia, Italy
[3] Mayo Clin Urol, Rochester, MN USA
[4] Ruhr Univ Bochum, Marien Hosp, Dept Urol, Herne, Germany
[5] McGill Univ, Jewish Gen Hosp, Hlth Ctr, Dept Radiat Oncol, Montreal, PQ, Canada
[6] Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Urol Res Inst, Dept Urol, Via Olgettina 60, Milan 20132, Italy
[7] Ludwig Maximilians Univ Munchen, Klinikum Univ Munchen, Urol Klin & Poliklin, Marchioninistr 15, Munich 81377, Germany
[8] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Urol, Amsterdam, Netherlands
[9] Univ Med Ctr Hamburg Eppendorf, Dept Urol, Hamburg, Germany
[10] Univ Zurich, Univ Hosp Zurich, Dept Urol, Zurich, Switzerland
[11] European Inst Oncol, Div Urol, Milan, Italy
[12] IRCCS Regina Elena Natl Canc Inst, Dept Urol, Rome, Italy
[13] La Paz Univ Hosp, Dept Urol, Madrid, Spain
[14] Inst Invest Hosp Univ La Paz IdiPAZ, Madrid, Spain
[15] Munchen Klin Bogenhausen, Dept Urol, Munich, Germany
[16] Med Univ Vienna, Vienna Gen Hosp, Comprehens Canc Ctr, Dept Urol, Vienna, Austria
[17] IM Sechenov First Moscow State Med Univ, Inst Urol & Reprod Hlth, Moscow, Russia
[18] New York Presbyterian Hosp, Weill Cornell Med Coll, Dept Urol, New York, NY USA
[19] Univ Texas Southwestern Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA
[20] Charles Univ Prague, Fac Med 2, Dept Urol, Prague, Czech Republic
[21] Univ Jordan, Jordan Univ Hosp, Dept Special Surg, Div Urol, Amman, Jordan
[22] Univ Jordan, Natl Ctr Diabet Endocrinol & Genet, Amman, Jordan
[23] Paris Descartes Univ, Bichat Hosp, Dept Urol, Paris, France
关键词
Bladder cancer; Clinical metastases; Induction chemotherapy; Multimodal treatment; Radical cystectomy; Urothelial cancer; TRANSITIONAL-CELL CARCINOMA; RADICAL CYSTECTOMY; NEOADJUVANT CHEMOTHERAPY; UROTHELIAL CARCINOMA; INDUCTION CHEMOTHERAPY; ADJUVANT CHEMOTHERAPY; OUTCOMES; METHOTREXATE; VINBLASTINE; METASTASES;
D O I
10.1007/s00345-020-03205-z
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose To assess the impact of perioperative chemotherapy on survival in cN+ BCa patients and analyze it according to the pN status. Methods A retrospective analysis was conducted on 639 BCa patients with cTanyN1-3M0 BCa treated with radical cystectomy (RC) and bilateral lymph node dissection (LND) with or without perioperative chemotherapy in ten tertiary referral centers from 1990 to 2017. Selected cN+ patients received induction chemotherapy (IC), whereas adjuvant chemotherapy (ACT) was delivered to selected pN+ patients. Univariable and multivariable Cox regression analyses were used to predict overall mortality (OM) after surgery, adjusting for clinicopathological confounders. Kaplan-Meier analyses assessed OM according to the treatment modality. Results Overall, 356 (56%) patients were treated with surgery alone, 155 (24%) with IC followed by surgery, and 128 (20%) with ACT following surgery. Over a median follow-up of 25 months, 316 deaths were recorded. At univariable analysis, patients treated with IC and surgery had lower OM both considering cN+ [hazard ratio (HR) 0.65, 95% confidence interval (CI) 0.49-0.87, p = 0.004] and cN+pN- patients (HR 0.61, 95% CI 0.37-0.99, p = 0.05) compared to those treated with surgery alone. cN+pN+ patients treated with ACT experienced lower OM compared to those treated with IC or surgery alone at multivariable analysis (HR 0.40, 95% CI 0.22-0.74, p = 0.003). Conclusion Patients with cTany cN+ cM0 BCa benefit more in terms of OS when treated with IC followed by RC + LND compared to RC + LND alone, regardless of LNMs at final histopathology examination. More data are needed to assess the role of ACT in the management of cN+ patients.
引用
收藏
页码:443 / 451
页数:9
相关论文
共 31 条
[1]   Management of muscle invasive, locally advanced and metastatic urothelial carcinoma of the bladder: a literature review with emphasis on the role of surgery [J].
Abufaraj, Mohammad ;
Gust, Kilian ;
Moschini, Marco ;
Foerster, Beat ;
Soria, Francesco ;
Mathieu, Romain ;
Shariat, Shahrokh F. .
TRANSLATIONAL ANDROLOGY AND UROLOGY, 2016, 5 (05) :735-744
[2]  
ALALAO O, 2019, UROL ONCOL
[3]   Cancer-specific mortality following radical cystectomy for bladder cancer with lymph node involvement: impact of pathologic disease features and adjuvant chemotherapy [J].
Clifton, Marisa M. ;
Psutka, Sarah P. ;
Boorjian, Stephen A. ;
Cheville, John C. ;
Thapa, Prabin ;
Thompson, R. Houston ;
Tollefson, Matthew K. ;
Karnes, R. Jeffrey ;
Frank, Igor .
WORLD JOURNAL OF UROLOGY, 2015, 33 (03) :373-379
[4]  
*COLL ABCM, 2004, COCHRANE DB SYST REV, V1, P1
[5]   Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer [J].
Galsky, Matthew D. ;
Stensland, Kristian D. ;
Moshier, Erin ;
Sfakianos, John P. ;
McBride, Russell B. ;
Tsao, Che-Kai ;
Casey, Martin ;
Boffetta, Paolo ;
Oh, William K. ;
Mazumdar, Madhu ;
Wisnivesky, Juan P. .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (08) :825-+
[6]   International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial [J].
Griffiths, Gareth .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (16) :2171-2177
[7]   Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer [J].
Grossman, HB ;
Natale, RB ;
Tangen, CM ;
Speights, VO ;
Vogelzang, NJ ;
Trump, DL ;
White, RWD ;
Sarosdy, MF ;
Wood, DP ;
Raghavan, D ;
Crawford, ED .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (09) :859-866
[8]   Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial [J].
Gschwend, Juergen E. ;
Heck, Matthias M. ;
Lehmann, Jan ;
Ruebben, Herbert ;
Albers, Peter ;
Wolff, Johannes M. ;
Frohneberg, Detlef ;
de Geeterg, Patrick ;
Heidenreich, Axel ;
Kaelble, Tilman ;
Stoeckle, Michael ;
Schnoeller, Thomas ;
Stenzl, Arnulf ;
Mueller, Markus ;
Truss, Michael ;
Roth, Stephan ;
Liehr, Uwe-Bernd ;
Leissner, Joachim ;
Bregenzer, Thomas ;
Retz, Margitta .
EUROPEAN UROLOGY, 2019, 75 (04) :604-611
[9]   Pathological downstaging and survival after induction chemotherapy and radical cystectomy for clinically node-positive bladder cancer-Results of a nationwide population-based study [J].
Hermans, Tom J. N. ;
van de Putte, Elisabeth E. Fransen ;
Horenblas, Simon ;
Meijer, Richard P. ;
Boormans, Joost L. ;
Aben, Katja K. H. ;
van der Heijden, Michiel S. ;
de Wit, Ronald ;
Beerepoot, Laurens V. ;
Verhoeven, Rob H. A. ;
van Rhijn, Bas W. G. .
EUROPEAN JOURNAL OF CANCER, 2016, 69 :1-8
[10]   Clinical prognosticators of survival in patients with urothelial carcinoma of the bladder and lymph node metastases after cystectomy with curative intent [J].
Horn, Thomas ;
Schmid, Sebastian C. ;
Seitz, Anna K. ;
Grab, Jessica ;
Wolf, Petra ;
Haller, Bernhard ;
Retz, Margitta ;
Maurer, Tobias ;
Autenrieth, Michael ;
Kuebler, Hubert R. ;
Gschwend, Jurgen E. .
WORLD JOURNAL OF UROLOGY, 2015, 33 (06) :813-819